Core Concepts
Histopathology reports in melanoma patients can predict immune-related adverse events during checkpoint inhibitor treatment.
Stats
Approximately 40% of patients stopped or changed checkpoint inhibitors due to immune-related adverse events.
Most patients (71.4%) experienced all-grade toxicities, and 28.2% experienced high-grade toxicities.
Patients with indeterminate lymphovascular invasion had significantly lower odds of developing all-grade immune-related adverse events than patients with lymphovascular invasion (adjusted odds ratio [aOR], 0.36).
The presence of NRAS mutation increased the patients' odds of developing all-grade immune-related adverse events (aOR, 2.56).
Quotes
"Routine histopathology reports may allow physicians to predict which patients with melanoma are the most likely to develop immune-related adverse events while taking checkpoint inhibitors."
"The presence of lymphovascular invasion and NRAS mutation were associated with increased odds of all-grade immune-related adverse events."